News headlines about Diffusion Pharmaceuticals (NASDAQ:DFFN) have been trending somewhat positive this week, Accern reports. The research group identifies positive and negative media coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Diffusion Pharmaceuticals earned a news sentiment score of 0.12 on Accern’s scale. Accern also gave media stories about the company an impact score of 45.0372480785099 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

DFFN stock traded up $0.01 during midday trading on Friday, hitting $0.40. The stock had a trading volume of 95,008 shares, compared to its average volume of 121,192. The stock has a market cap of $19.32 million, a price-to-earnings ratio of -0.35 and a beta of -1.75. Diffusion Pharmaceuticals has a 52-week low of $0.31 and a 52-week high of $2.97.

Diffusion Pharmaceuticals (NASDAQ:DFFN) last issued its quarterly earnings results on Monday, August 13th. The company reported ($0.05) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.06) by $0.01. equities research analysts predict that Diffusion Pharmaceuticals will post -0.42 earnings per share for the current year.

A number of research firms recently weighed in on DFFN. HC Wainwright restated a “buy” rating and issued a $1.25 target price on shares of Diffusion Pharmaceuticals in a research report on Monday, August 20th. ValuEngine upgraded Diffusion Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, June 2nd.

Diffusion Pharmaceuticals Company Profile

Diffusion Pharmaceuticals Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer. Its lead product candidate is transcrocetinate sodium, which has initiated Phase 3 trials for the treatment of glioblastoma multiforme (GBM); Phase 2 clinical trials for the treatment of pancreatic cancer; Phase 2/3 clinical trials for the treatment of metastatic brain cancer; and Phase 2 trial for the treatment of stroke.

Recommended Story: Stock Symbols and CUSIP Explained

Insider Buying and Selling by Quarter for Diffusion Pharmaceuticals (NASDAQ:DFFN)

Receive News & Ratings for Diffusion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diffusion Pharmaceuticals and related companies with's FREE daily email newsletter.